{"entity":{"id":"paper-nci9673-nivolumab-metastatic-anal-cancer-morris-lancet-oncol-2017","kind":"paper","name":"NCI9673: nivolumab for previously treated unresectable metastatic anal cancer","aka":[],"tldr":"In the first completed immunotherapy trial for anal cancer, the PD-1 antibody nivolumab shrank tumours in a quarter of heavily pretreated patients with few side effects.","summary":"Multicentre single-arm phase 2 trial: 37 patients with previously treated metastatic squamous cell carcinoma of the anal canal received nivolumab 3 mg/kg every two weeks.\n\nNine patients (24 percent, 95% CI 15 to 33) responded, two completely and seven partially. Grade 3 adverse events were anaemia (2), fatigue, rash and hypothyroidism (1 each); there were no serious adverse events.","asOf":"2026-09-22","links":[{"label":"Lancet Oncol 2017","url":"https://doi.org/10.1016/S1470-2045(17)30104-3"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/28223062/"}],"tags":[],"related":[],"cancers":["metastatic-anal-cancer","anal"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nci9673"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"journal":"The Lancet Oncology","year":2017,"doi":"10.1016/S1470-2045(17)30104-3","pmid":"28223062","authors":"Morris VK, Salem ME, Nimeiri H, et al.","paperType":"observational","findings":["Objective response 24 percent (95% CI 15 to 33): 2 complete and 7 partial responses in 37 patients.","Grade 3 adverse events in 5 patients; no serious adverse events."],"whatItMeans":"PD-1 blockade is an option for metastatic anal cancer after chemotherapy, and the basis for later immunotherapy combinations in the disease.","caveats":["Single-arm design with 37 patients."],"changedPractice":true,"participants":37},"route":"/key-papers/paper-nci9673-nivolumab-metastatic-anal-cancer-morris-lancet-oncol-2017/","neighbours":{"cancer":[{"id":"anal","kind":"cancer","name":"Anal cancer (squamous cell carcinoma)","route":"/cancers/anal/"},{"id":"metastatic-anal-cancer","kind":"cancer","name":"Metastatic and recurrent anal squamous cell carcinoma","route":"/cancers/metastatic-anal-cancer/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"trial":[{"id":"nci9673","kind":"trial","name":"NCI9673","route":"/trials/nci9673/"}],"journal":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}